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UNAIDS estimates that there were 4.9 million new HIV
infections in the year 2004, and that 640 000 of these infections
occurred in children less than 15 years old.1 The first national
population-based survey conducted in South Africa in 20022
showed that 9.3% of persons between the ages of 15 and 24
years of age were HIV-positive and that female youth were
more likely to be HIV-infected than male youth (Table I).  In
South Africa sexual debut is at an early age,3 with 50% of
adolescents sexually active by the age of 15. Transgenerational
sex, transactional sex and non-consensual sex put adolescent
girls at high risk for acquiring HIV infection.4
National antenatal data show that the prevalence of HIV in
women < 20 years old rose from 15.8% in 2003 to 19.5% in
2004, indicating that the epidemic is being fuelled by incident
infection during adolescent years.5 Approximately 1 million
women give birth each year in South Africa, with more than
250 000 of these infants being born to HIV-infected mothers.
Although there are programmes in place to prevent mother-to-
child transmission (MTCT), most of the interventions currently
available only impact on intrapartum and early postpartum
transmission, and have minimal impact on prevention of
postnatal transmission through breast-feeding.6 Whatever the
route of infection, it is clear that both infant children and
adolescents are at the highest risk of HIV infection.  This
epidemiological fact makes it imperative that an HIV vaccine
target this group to have any hope of successful epidemic
control. We should not withhold the availability of a vaccine to
this population because of lack of data through delays in
clinical trial work.
There are many promising HIV vaccine candidates in or
about to enter human clinical trials.  The road to the licensing
of a successful candidate is long, since phase I - III trials
usually take at least 10 years.  No preventive HIV vaccine trials
have included adolescents, and only 2 completed trials have
targeted neonates.7-9 In South Africa, in order to license a
vaccine for use in children and adolescents, data must exist on
the safety, immunogenicity and efficacy of the vaccine in
children and adolescents, although exact criteria for approval
have not yet been defined.  In the past, vaccine trials in young
children and infants have been accelerated because of the
existence of correlates of immunity to the disease; however,
since the immune marker necessary for protection against HIV
is not yet defined, the task of approving a vaccine for infants,
children and adolescents is arduous and may take longer than
usual.  
As there are physiological differences between children and
adults, one cannot necessarily extrapolate adult data to
children. Surface area, body mass and metabolic differences
affect the dosage and safety profile of drugs and vaccines.  The
bioavailability and safety of vaccines is affected by
physiological differences such as increased liver size, immature
liver enzymes, decreased renal clearance, and increased blood-
brain-barrier permeability, among others.  In addition, the
immune response to vaccines is different in infants, and
probably in adolescents.  Here we review the differences
between the immune systems and response to vaccination in
children (both infants and adolescents) versus adults.   
The immune system, an overview
Generally, the immune response has two arms; humoral and
cellular.10 The adaptive cellular immune response is mediated
by B- and T-lymphocytes.  B-lymphocytes mature into plasma
cells and produce antibody.  T-cells either express CD4 or CD8
on their surface, and are known as CD4+ helper T-cells (Th)
and cytotoxic T-lymphocytes (CTLs) respectively.  Th cells
primarily exert their helper functions through secretion of
soluble proteins called cytokines.  CTLs are thought to be very
important in the initial control of HIV infection and kill
infected cells by lysis and/or apoptosis.
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Table I. HIV prevalence by age group from the HSRC
National Survey, South Africa, 20022
Percentage 
Age N HIV-positive 95% CI
Children 
(2 - 14 years) 2 348 5.6 3.7 - 7.4
Youth 9.3 (12% females,
(15 - 24 years) 2 099 6% males) 7.3 - 11.2
Adults 
(> 25 years) 3 981 15.5 13.5 - 17.5
Total 8 428 11.4 10.0 - 12.7




The immaturity of the infant immune system is demonstrated
by the increased susceptibility of children to infections by both
viral and bacterial pathogens.  The humoral arm of the
immune system is underdeveloped and differs greatly from
that of adults. Infants only develop the ability to make a
significant amount of immunoglobulins at around 6 - 12
months of life.  Maternal immunoglobulin G (IgG) is actively
transported across the placenta predominantly during the third
trimester, and is present at high levels.  Maternal immuno-
globin A (IgA) is secreted in breast-milk.10 These passively
acquired antibodies can alter the antibody-dependent response
to immunogens in as long as 18 months in infants of infected or
immunised mothers, but other cellular immunity seems less
affected by maternal antibody.  
There are less obvious impairments in the T-cell repertoire of
the infant immune system.  Antigen-specific T-cell precursors
are lower in neonates than in adults.11 Differences in cytokine
profiles exist and may be responsible for much of the poor
capabilities of the developing immune system and an impaired
induction of cytotoxic CD8 T-cells.12,13
Puberty is characterised by an increase in gonadotropic
hormones which promote the secretion of androgens and
oestrogens in both boys and girls.  There is direct evidence that
immunology and sex steroids are linked both at the
physiological and cellular level. Post-pubertal females are at
increased risk for autoimmunity, which strongly suggests that
sex steroids affect immune function.  Most cells of the immune
system express both intra and extracellular receptors for sex
steroids.14 In addition to the effects of pubertal hormones on
immunity, there are quantitative differences in the cells of the
immune system between infants, children, adolescents and
adults.
Since there are vast differences in all arms of the immune
system between different age groups, it is difficult to predict
responses to vaccinations without actual clinical trials.
Paediatric responses to vaccination
HIV vaccinology has required innovative approaches to
vaccine design.15,16 Briefly, the live-attenuated vaccine approach
is considered too risky for use in a human HIV vaccine, killed
virus is poorly immunogenic, subunit vaccines are unlikely to
elicit neutralising antibodies and are poor T-cell stimulants,
and some promising DNA vaccines and vector-based vaccines
are in phase I and II trials at the moment.
At birth, the ability to respond to antigens is greatest for
protein antigens and less for glycoproteins and polysaccha-
rides.17 The decreased response to some vaccinations is
thought to be due partly to the effects of maternal antibody.
However, the degree of passive antibody influence varies
according to vaccine.  In general, passively acquired antibodies
may suppress humoral response to active immunisation in the
first few months of life dependent on the maternal antibody/
vaccine antigen ratio, but do not affect the response to
boosting.18 Maternal antibody seems to have less of an effect
on T-cell responses.18 T-cell response to vaccination can also
differ in early life.  Neonatal Th1 responses are not easily
elicited with conventional vaccines capable of eliciting Th1
responses in adults.19
There are multiple viral and bacterial vector-based HIV
vaccines in human trials and in the pipeline (www.iavi.org;
www.hvtn.org).  Pre-existing titres to the vector delivery
system can affect the response to the immunogen and therefore
can be affected by age.  For example, schoolchildren may have
higher adenoviral titres, although age-related adenoviral titres
are yet to be determined in South Africa.  
In addition to theoretical differences in the immune response
that children may have to vaccines, there are many examples in
vivo of how children and adolescents behave differently to
specific vaccines (Table II).  There are limited human data on
age-related responses to HIV vaccine candidates; however, the
first preventive trial in neonates born to HIV-1 infected
mothers used recombinant gp120.  About one-third of the
infants were able to mount lymphoproliferative and antibody
responses.20,21 An important finding was that the antibody
response in the accelerated schedule subjects was not affected
by the higher levels of maternal antibody found at earlier age.
Current HIV envelope vaccine candidates elicit high gp120
antibody titres, but neutralising antibody is difficult to elicit.16
There are not a lot of data on vector vaccine approaches,
other than data for gene therapy.  There have been HIV vaccine
trials involving poxvirus vectors in HIV-exposed neonates.
PACTG 326 part I evaluated the safety and immunogenicity of
ALVAC vCP205 (high dose versus low dose) in neonates born
to HIV-infected mothers.  This canarypox vector contains HIV-1
subtype B envelope genes, plus gag and pol genes.  Lympho-
proliferative and CTL responses were present in about one-
third of vaccine recipients.  CTL responses were detected as
early as 6 weeks of age.9 Another arm of PACTG 326, a phase
I/II study of ALVAC-HIV vCP1452, a modified recombinant
canarypox expressing multiple HIV-1 genes alone or with
Envelope (AIDSVAX B/B), also showed lymphoproliferative
and CTL responses in a few subjects at preliminary analysis.22
Discussion
The development of a vaccine for paediatric and adolescent use
is an urgent global priority.  There is a complex interplay
between age and immune function, which will make responses
to vaccination difficult to predict.  Additionally, adolescence, a
time of rapid physiological change, also poses potential
immunological challenges.  Almost every vaccine category has
an example of an age-dependent response.  We cannot just
expect that a vaccine that shows promise in adults is going to
be safe, immunogenic and efficacious in children.  To enrol
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only adults in HIV vaccine research will result in even greater
delay for the benefits of a vaccine to reach children and
adolescents, owing to the requirement for safety,
immunogenicity and efficacy data in the age groups for which
the vaccine will be licensed.  The window of opportunity exists
to ensure that this information is gathered now, and delay for
whatever reason can be seen as a failure to safeguard our most
vulnerable population.
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Table II. Age-related responses to vaccines for pathogens
other than HIV according to vaccine type
Vaccine type Pathogen Age-related response
Live Mumps Seroconversion rates for
attenuated mumps-susceptible Swedish 
toddlers were 95%, versus only 
80% in adolescents.23
Seroconversion rates to mumps 
vaccination are generally 
slightly lower in adults than in 
children
BCG In the pubertal period 
androgen levels have an effect 
on BCG immune response. 
Responses to BCG vaccination 
via tuberculin test were affected
by pubertal stage, and testicular
volume24
Varicella Administered to children < 13 
years of age, induces protective 
antibodies in > 95% of 
recipients after a single dose. 
For susceptible persons > 13 
years of age, 2 doses separated 
by 4 - 8 weeks are 
recommended25
Killed Hepatitis A The dosage of both forms of 
inactivated hepatitis A vaccines 
licensed in the USA are half of 
the adult dose in those 2 - 18 
years of age
Protein Hepatitis B Adolescents may require only 2
subunit doses26
RTS,S/AS02A A 3-dose phase IIb in 1 - 4-year-
olds showed efficacy for the
first clinical episodes of 29.9%.  
Efficacy for severe malaria was 
57.7%.  Immunogenicity was
greater in the < 24-month age
group.  There was no evidence
of waning efficacy against
clinical disease and limited
waning efficacy against
infection. This sustained
protection was not found in
trials in malaria-naïve
volunteers or Gambian 
adults27-29
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